2019
Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
Epperla N, Costa L, Vaughn J, Hanel W, Raya S, Cashen A, Sarmad R, Badar T, Hamadani M, Liu Y, Barta S, Caimi P, Sethi T, Reddy N, Burkart M, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Ballard H, Svoboda J, Emery L, Lansigan F, Glenn M, Churnetski M, Cohen J, Sorge C, Xavier A. Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure. Blood 2019, 134: 1554. DOI: 10.1182/blood-2019-129199.Peer-Reviewed Original ResearchPR/stable diseasePrimary treatment failureClassical Hodgkin lymphomaAnthracycline-containing chemotherapy regimensOutcomes of patientsHigh-dose chemotherapyStable diseaseOverall survivalER cohortComplete remissionSeattle GeneticsSpeakers bureauPP cohortSalvage therapyChemotherapy regimensProgressive diseasePartial responseTreatment failureHodgkin's lymphomaNew agentsAdvanced-stage classical Hodgkin lymphomaFive-year overall survivalRelapsed classical Hodgkin lymphomaAutologous hematopoietic cell transplantationRefractory classical Hodgkin lymphoma
2017
Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies
Sethi TK, Basdag B, Bhatia N, Moslehi J, Reddy NM. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies. Current Hematologic Malignancy Reports 2017, 12: 257-267. PMID: 28233150, DOI: 10.1007/s11899-017-0369-y.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCardiovascular side effectsHematologic malignanciesSide effectsUnique side effect profileCardiovascular adverse eventsSide effect profileLong-term administrationNon-Hodgkin lymphomaChronic myeloid leukemiaTyrosine kinase inhibitorsYears of ageOrgan-specific toxicityAdverse eventsFace of treatmentTargeted agentsEffect profilePatient populationCardiovascular toxicityMyeloid leukemiaNew agentsPreemptive managementMalignancyPrior exposureKinase inhibitorsProteasome inhibitors